Post

💊 $JNJ Johnson & Johnson issued a strong bearish guidance cut on July 29, flagged by InsiderWatch's 8-K tracker as a material Item 7.01 filing—the company's most significant equity signal in weeks. The guidance reduction marks a sharp reversal from recent investor expectations. The same day, low-conviction insider activity continued to cluster—five days of two-filing-per-day Form 4 submissions ending July 28 suggest routine executive transactions proceeding as scheduled despite the guidance miss, a muted response from the C-suite. On the Hill, the signal split. Rep. Lloyd Doggett (D-TX) purchased JNJ stock on July 6 with a 27-day disclosure lag, a strong bullish Congressional trade. But two weeks later, when guidance landed, Hon. Thomas H. Kean Jr. (R-NJ) filed partial sales of up to $15,000 each on July 15—a light bearish Congressional read that arrived with a notable 43-day delay in one instance, suggesting the trade predated the public guidance miss. The mixed Congressional tone and insider indifference suggest the market may still be pricing the earnings reset.